title: Detectable Wilms' tumor-1 transcription at treatment completion is associated with poor prognosis of acute myeloid leukemia: a single institution's experience.
abstract: OBJECTIVE
  The present retrospective study was conducted to measure Wilms' tumor-1 (WT1) mRNA levels in the peripheral blood of patients with acute myeloid leukemia (AML) in order to examine any association with the clinical outcomes.
  
  
  METHODS
  A total of 58 AML patients were evaluated retrospectively in our institution. WT1 transcripts were determined by real-time reverse transcriptase-polymerase chain reaction in peripheral blood samples.
  
  
  RESULTS
  WT1 levels at diagnosis did not vary according to response of induction treatments, and the levels were comparable between the patients with durable remission and the patients with relapse of disease. WT1 levels at the completion of the treatment were higher in the group with relapse of disease than in the group with sustained remission. Detectable WT1 transcripts after the completion of chemotherapy courses were associated with poor prognoses.
  
  
  CONCLUSIONS
  WT1 mRNA levels at treatment completion may predict for prognosis of AML.
authors.affiliation: Department of Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, 23 Shimoaizuki, Matsuoka, Eiheiji Fukui, 910-1193, Japan. tyamauch@u-fukui.ac.jp
authors.forename: Takahiro
authors.initials: T
authors.lastname: Yamauchi
authors.forename: Eiju
authors.initials: E
authors.lastname: Negoro
authors.forename: Shin
authors.initials: S
authors.lastname: Lee
authors.forename: Mihoko
authors.initials: M
authors.lastname: Takai
authors.forename: Yasufumi
authors.initials: Y
authors.lastname: Matsuda
authors.forename: Kazutaka
authors.initials: K
authors.lastname: Takagi
authors.forename: Shinji
authors.initials: S
authors.lastname: Kishi
authors.forename: Katsunori
authors.initials: K
authors.lastname: Tai
authors.forename: Naoko
authors.initials: N
authors.lastname: Hosono
authors.forename: Toshiki
authors.initials: T
authors.lastname: Tasaki
authors.forename: Satoshi
authors.initials: S
authors.lastname: Ikegaya
authors.forename: Akira
authors.initials: A
authors.lastname: Yoshida
authors.forename: Yoshimasa
authors.initials: Y
authors.lastname: Urasaki
authors.forename: Hiromichi
authors.initials: H
authors.lastname: Iwasaki
authors.forename: Takanori
authors.initials: T
authors.lastname: Ueda
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D015973:Gene Expression Regulation, Leukemic; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D016019:Survival Analysis; D013997:Time Factors; D014158:Transcription, Genetic; D016896:Treatment Outcome; D025721:WT1 Proteins / Q000235:genetics* / Q000378:metabolism; D055815:Young Adult
chemical_list: D012333:RNA, Messenger; D025721:WT1 Proteins; C583751:WT1 protein, human
keywords: AML; MRD; WT-1; relapse